Dharmesh Kant, now with Motilal Oswal, is diligently discharging his responsibility of identifying winning stocks and recommending them to us. He has now homed in on a top-quality stock which stands to benefit from the demand for specialty chemicals and pharmaceuticals
Dharmesh Kant’s latest stock pick is a top-quality and well managed company with a long and successful track record. It enjoys a high “entry barrier” and a “moat” and has high return ratios
Today, there was great excitement in the air over the news that IndiaNivesh had sold off a huge chunk of Camson Bio-Tech, a stock earlier recommended by them. Have they lost confidence in the stock and does it spell doom for us?
Recent Comments